Status:
COMPLETED
Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Primary Raynaud Disease
Systemic Sclerosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Ve-cadherin is expressed in endothelial cells. Systemic slerosis is a rare auto-immune disease with a endothelial dysfunction. This study is to evaluated the level of soluble VE-cadherin and VE-cadher...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- group 1: systemic sclerosis
- group 2: raynaud primary disease
Exclusion
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT02212249
Start Date
May 1 2014
End Date
March 1 2016
Last Update
March 24 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Grenoble University Hospital
Grenoble, France, 38043